NASDAQ:IRTCIrhythm Technologies Stock Price, Forecast & News

Irhythm Technologies' stock was trading at $85.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, IRTC shares have increased by 136.2% and is now trading at $202.07.
View which stocks have been most impacted by Coronavirus.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Irhythm Technologies in the last year. There are currently 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Irhythm Technologies.

Irhythm Technologies is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Irhythm Technologies.

Irhythm Technologies Inc (NASDAQ:IRTC) announced its quarterly earnings data on Thursday, August, 6th. The company reported ($0.75) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.84) by $0.09. The company earned $50.88 million during the quarter, compared to analysts' expectations of $42.18 million. Irhythm Technologies had a negative net margin of 24.34% and a negative return on equity of 49.99%. The firm's revenue for the quarter was down 3.0% compared to the same quarter last year. During the same period last year, the business posted ($0.43) earnings per share.
View Irhythm Technologies' earnings history.

10 brokers have issued 12 month target prices for Irhythm Technologies' stock. Their forecasts range from $130.00 to $200.00. On average, they expect Irhythm Technologies' stock price to reach $166.38 in the next twelve months. This suggests that the stock has a possible downside of 17.7%.
View analysts' price targets for Irhythm Technologies.

News headlines about IRTC stock have trended very negative recently, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Irhythm Technologies earned a media sentiment score of -3.4 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term.
View the latest news about Irhythm Technologies.

Some companies that are related to Irhythm Technologies include Teleflex (TFX), ABIOMED (ABMD), Insulet (PODD), Penumbra (PEN), Novocure (NVCR), Tandem Diabetes Care (TNDM), Hill-Rom (HRC), Globus Medical (GMED), Nevro (NVRO), Integra Lifesciences (IART), Haemonetics (HAE), ICU Medical (ICUI), Inovio Pharmaceuticals (INO), Inari Medical (NARI) and Inspire Medical Systems (INSP).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Irhythm Technologies investors own include Alibaba Group (BABA), NVIDIA (NVDA), DexCom (DXCM), Paypal (PYPL), Teladoc Health (TDOC), Shopify (SHOP), Veeva Systems (VEEV), Advanced Micro Devices (AMD), Cisco Systems (CSCO) and Paycom Software (PAYC).

(IRTC) raised $76 million in an IPO on Thursday, October 20th 2016. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

Irhythm Technologies trades on the NASDAQ under the ticker symbol "IRTC."

Irhythm Technologies' stock is owned by many different institutional and retail investors. Top institutional investors include TimesSquare Capital Management LLC (2.27%), New York State Common Retirement Fund (2.02%), Victory Capital Management Inc. (1.87%), Great Lakes Advisors LLC (0.55%), Swiss National Bank (0.22%) and First Trust Advisors LP (0.20%). Company insiders that own Irhythm Technologies stock include Bruce G Bodaken, David A Vort, Derrick Sung, Kevin M King, Matthew C Garrett, Merz Cathleen Noel Bairey, Ralph Snyderman and Raymond W Scott.
View institutional ownership trends for Irhythm Technologies.

IRTC stock was sold by a variety of institutional investors in the last quarter, including TimesSquare Capital Management LLC, Great Lakes Advisors LLC, Principal Financial Group Inc., CWM LLC, Mutual of America Capital Management LLC, Mitsubishi UFJ Kokusai Asset Management Co. Ltd., Envestnet Asset Management Inc., and SG Americas Securities LLC. Company insiders that have sold Irhythm Technologies company stock in the last year include David A Vort, Kevin M King, Matthew C Garrett, Ralph Snyderman, and Raymond W Scott.
View insider buying and selling activity for Irhythm Technologies.

IRTC stock was acquired by a variety of institutional investors in the last quarter, including Columbus Circle Investors, First Trust Advisors LP, Victory Capital Management Inc., NN Investment Partners Holdings N.V., NN Investment Partners Holdings N.V., Swiss National Bank, Roubaix Capital LLC, and Virtu Financial LLC.
View insider buying and selling activity for Irhythm Technologies.

Shares of IRTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IRTC stock can currently be purchased for approximately $202.07.

Irhythm Technologies has a market capitalization of $5.46 billion and generates $214.55 million in revenue each year. The company earns $-54,570,000.00 in net income (profit) each year or ($2.16) on an earnings per share basis. Irhythm Technologies employs 748 workers across the globe.

The official website for Irhythm Technologies is www.irhythmtech.com.

Irhythm Technologies' mailing address is 650 TOWNSEND STREET SUITE 500, San Francisco CA, 94103. The company can be reached via phone at 415-632-5700 or via email at [email protected]